U.S. Markets closed

The High Hope of Exelixis’s Cabometyx Label Expansion

Margaret Patrick

Exelixis (EXEL) plans to explore Cabometyx in combination with immune checkpoint inhibitors such as atezolizumab, ipilimumab, and nivolumab.